about
The influence of UGT polymorphisms as biomarkers in solid organ transplantationDiabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen.Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.Acquired hypogammaglobulinemia in HIV-positive subjects after liver transplantation.Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients.The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?Optimization of pediatric rheumatology therapeutics.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.Genes and beans: pharmacogenomics of renal transplant.Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.Pharmacogenetics and immunosuppressive drugs.Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation.
P2860
Q27009825-C89AE5A5-458A-4633-B453-6C4129969D05Q34702634-D214F44A-CD65-4C75-A0A2-B2DE76737E86Q35112606-C9503AE5-DF19-4F41-8BB8-9C7EE0B302D3Q36629233-F3E722D3-A91F-4854-BAEB-F01BC31A691BQ37373123-D33E0A4B-65BB-48DE-A0CE-AD5BB87E67F7Q37452521-E8ADF3E5-5AA2-4D43-8BE0-68B7878DC4CCQ37857285-CD3E19F7-81DB-4BA8-8B74-F86DE0EB0560Q37956717-29A302E3-2ACC-46E7-AC63-F6E69491A3D9Q37991520-0673EFB1-2C8A-4B70-861E-C55E79546A72Q38087925-3B6EC913-0566-4C03-9E1D-FDFBCF395683Q38092131-17E0BB49-32CC-4E4B-9073-F07C4888B1C7Q38104742-24AD5553-74CF-4EFE-B8B5-E5329C4FCB5BQ38208983-14E2B0B2-C6E7-434C-8BA2-C2BFCDB1DCF7Q38223136-A99399B0-FB40-4A93-A1CF-308F469FB3FBQ38253383-1DE4FBFF-52B5-4203-B921-CD8F4464D4B0Q38258677-D199017A-6A85-47A2-85E0-49CB82BED259Q46372141-B830A128-0E52-44A4-9A4B-7810DEA03232
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetic influences on mycophenolate therapy.
@en
Pharmacogenetic influences on mycophenolate therapy.
@nl
type
label
Pharmacogenetic influences on mycophenolate therapy.
@en
Pharmacogenetic influences on mycophenolate therapy.
@nl
prefLabel
Pharmacogenetic influences on mycophenolate therapy.
@en
Pharmacogenetic influences on mycophenolate therapy.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacogenetic influences on mycophenolate therapy.
@en
P2093
Christine E Staatz
Katherine A Barraclough
Katie J Lee
P2860
P304
P356
10.2217/PGS.10.9
P577
2010-03-01T00:00:00Z